Real-world performance of the Omnipod 5 automated insulin delivery (AID) system in >7500 children and adolescents with type 1 diabetes in the United Kingdom

Published Date: 01st February 2025

Publication Authors: Campbell. FM, Willemsen. RH, Huyett. LM, Mendez. JJ, Hadjiyianni. I

Conference Abstract

Aims: The Omnipod 5 AID System, which allows for personalised therapy through customisable glucose targets, is CE marked for use in individuals ages 2 years and older with type 1 diabetes and is commercially available in some European countries. This study aimed to evaluate real-world performance of the system in paediatric users in the United Kingdom (UK).
Method(s): A retrospective analysis of continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users with type 1 diabetes aged two to <18 years using >=five units of insulin per day in the UK whose guardian provided consent and who had >=90 days of data with sufficient CGM data (>=75% of days with >=220 readings) available in the cloud-based data management system was conducted.
Result(s): Data from 7529 users were available at the time of analysis (median 257 days of use). Users achieved a median time in target range (TIR; 3.9-10.0 mmol/L) of 66.2% (n = 3816), 64.6% (n = 2433) and 61.4% (n = 1280) with use of the 6.1, 6.7 and 7.2-8.3 mmol/L targets, respectively. Time below range (TBR; <3.9 mmol/L) was low (median <=1.77%) across glucose targets. Use of the lowest target (used by 50.7% of all users) was associated with the highest TIR and minimal TBR.
Conclusion(s): Collectively, these real-world results demonstrate favourable outcomes with Omnipod 5 use in children and adolescents with type 1 diabetes in the UK. These findings support that healthcare providers should consider encouraging users seeking to further improve TIR to decrease their glucose target towards the lowest setting whenever possible.

Campbell, F.M.; Ng, S.M.; Willemsen, R.H.; Huyett, L.M.; Mendez, J.J.; Hadjiyianni, I. (2025). Real-world performance of the Omnipod 5 automated insulin delivery (AID) system in >7500 children and adolescents with type 1 diabetes in the United Kingdom. Diabetic Medicine. 42(Supp 1). [Online]. Available at: https://dx.doi.org/10.1111/dme.15498 [Accessed 4 February 2026].